Lovelace biomedical and environmental research institute: to perform non-clinical safety assessment of TTHX1114 to support fuchs endothelial corneal dystrophy IND application.
Ended Awarded Last action
- Contract number
- 75N95018F00002
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,805,430
Award facts
- Opportunity
-
- CRO Support for NCATS In Vitro and In Vivo Toxicology Studies Pre-Solicitation · N01TR172002 · Posted Apr 7, 2020
- CRO Support for NCATS In Vitro and In Vivo Toxicology Studies Award Notice · Posted May 2, 2016
- Contract value 100% obligated
- $2,805,430.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$156,237 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $614,142 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $269,354 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $629,448 | |
| Exercise an Option | $565,374 | |
| Original award | $883,350 |
About this award
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $2,805,430.26 Cost Plus Fixed Fee contract to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization, to perform non-clinical safety assessment of TTHX1114 to support a Fuchs Endothelial Corneal Dystrophy Investigational New Drug (IND) application. This contract was issued as a Delivery Order under the "CRO Support for NCATS In Vitro and In Vivo Toxicology Studies" Indefinite Delivery Indefinite Quantity (IDIQ) contract vehicle. The contract has no set-aside designation and is focused on providing preclinical research and testing services to support the development of pharmaceuticals and other health-related products.
Quick answers
Who was awarded contract 75N95018F00002?
75N95018F00002 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 17, 2018.
How much is contract 75N95018F00002 worth?
The government has obligated $2,805,430 on 75N95018F00002.
Which agency awarded contract 75N95018F00002?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95018F00002, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95018F00002 an order under another contract?
Yes. 75N95018F00002 is a delivery order under HHSN271201700017I, an indefinite delivery contract, on CRO Support for NCATS In Vitro and In Vivo Toxicology Studies.
Was contract 75N95018F00002 competed?
The extent of competition for 75N95018F00002 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award